On 21 March 2024, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization (MA) for Outlook Therapeutics’ Lytenava (ONS-5010, bevacizumab gamma), intended for treatment of neovascular (wet) age-related macular degeneration (nAMD).
EMA recommends approval of bevacizumab Lytenava
Biosimilars/News
|
Posted 22/05/2024
0
Post your comment
![Blue eye with data points Blue eye with data points](/var/gabi/storage/images/media/images/blue-eye-with-data-points/164730-1-eng-GB/blue-eye-with-data-points_large.jpg)
Bevacizumab is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers [1]. The originator reference product is Roche’s originator, Avastin.
Lytenava/ONS-5010 (bevacizumab gamma), an investigational ophthalmic formulation of bevacizumab for the treatment of wet AMD and other retinal diseases. As US Food and Drug Administration (FDA) or European Commission (EC) approved ophthalmic bevacizumab formulations are lacking, clinicians resort to repackaged intravenous (IV) bevacizumab from compounding pharmacies, which pose contamination and potency risks. Lytenava/ONS-5010, if approved, would offer physicians a sanctioned option for treating wet AMD.
Outlook Therapeutics is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.
The CHMP positive opinion was based on results from Outlook Therapeutics’ wet AMD clinical programme for ONS-5010, which consists of three completed registration clinical trials – NORSE ONE, NORSE TWO and NORSE THREE, as well as studies and bibliographic literature substituting or supporting certain tests and studies. If approved, an initial 10 years of market exclusivity in the European Union (EU) is expected for ONS-5010/LYTENAVA.
Pending the decision/approval of the MA from the EC, Lytenava will be available as 25 mg/mL solution for injection in Europe.
However, following the submission of their Biologics License Application (BLA) in the US, in August 2023, the FDA did not approve Lytenava and issued a complete response letter (CRL). In this letter, the FDA acknowledged that Outlook Therapeutics’ NORSE TWO pivotal trial met its safety and efficacy endpoints. However, the FDA stated that they could not approve the BLA during this review cycle due to 'several CMC issues, open observations from preapproval manufacturing inspections, and a lack of substantial evidence'.
Related articles
Dr Reddy's launches bevacizumab biosimilar Versavo in the UK
FDA approves bevacizumab biosimilar Avzivi
LATIN AMERICAN FORUM View the latest headline article: Bio-Thera y SteinCares firman acuerdo para comercializar dos biosimilares en LATAM Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANO Ver el último artículo de cabecera: Bio-Thera y SteinCares firman acuerdo para comercializar dos biosimilares en LATAM !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. |
Reference
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of bevacizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 May 22]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-bevacizumab
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.
Research
Budget impact analysis of Rixathon introduction in Chile for non-Hodgkin lymphoma
Biosimilars in inflammatory bowel disease: are we ready for multiple switches
General
Humira's resilience in the face of biosimilar competition
Boehringer Ingelheim to expand access to adalimumab biosimilar
Richmond to launch similar biologicals bevacizumab Yriviak and adalimumab Armixa
![01 AA007239 01 AA007239](/var/gabi/storage/images/media/images/01-aa007239/21704-1-eng-GB/01-AA007239_large.jpg)
Biosimilars/News Posted 06/08/2024
The best selling biotechnology drugs of 2008: the next biosimilars targets
![picture09 picture09](/var/gabi/storage/images/media/images/picture09/2207-2-eng-GB/picture09_large.jpg)
Post your comment